Gilead Expands Hep C Efforts In $11B Skadden-Led Buy
Biopharmaceutical company Gilead Sciences Inc. will acquire Princeton, N.J.-based Pharmasset Inc. for $11 billion in cash in a bid to accelerate development of an all-oral regimen for the treatment of the...To view the full article, register now.
Already a subscriber? Click here to view full article